Theravance Biopharma TBPH Yupelri Monotherapy — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's yupelri monotherapy — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's yupelri monotherapy — revenue?
- Theravance Biopharma (TBPH) reported yupelri monotherapy — revenue of $21.85M in Q1 2026.
- How has Theravance Biopharma's yupelri monotherapy — revenue changed year-over-year?
- Theravance Biopharma's yupelri monotherapy — revenue increased by 7.0% year-over-year, from $20.42M to $21.85M.
- What is the long-term trend for Theravance Biopharma's yupelri monotherapy — revenue?
- Over 4 years (2021 to 2025), Theravance Biopharma's yupelri monotherapy — revenue has grown at a 13.3% compound annual growth rate (CAGR), from $56.68M to $93.31M.
- What does yupelri monotherapy — revenue mean?
- This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product or therapeutic monotherapy. It reflects the market adoption and commercial performance of the drug within its target patient population. Monitoring this trend is essential for assessing the product's lifecycle stage and its contribution to the company's top-line growth.